Google
TGTX — TG THERAPEUTICS INC (Healthcare >> Biotechnology)
TGTX FAQ
What is TGTX's P/E ratio?
TG THERAPEUTICS INC (TGTX) currently trades at a P/E ratio of 12.14.
What is TGTX's ROE?
TG THERAPEUTICS INC reports a Return on Equity (ROE) of 79.21%.
What is TGTX's dividend yield?
TG THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TGTX's Deepscope Quality Score?
Deepscope rates TGTX's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TGTX?
Deepscope's AI Timing Score for TGTX is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TGTX belong to?
TG THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 40.11
Price
3.47
(9.47%)
Day Change
|
|
|---|
TGTX, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
63% |
| In Recommendations? | In "Invest - GROWTH" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
243
|
| Magic Formula Rank by ROE |
243
|
| Magic Formula Rank by ROIC |
376
|
| Price | 40.11 |
| PBV / Sector |
9.62 / 4.48
|
| Earning Per Share | 3.30 |
| PE / Sector |
12.14 / 16.68
GOOD
|
| PEG or PE/Growth / Sector |
0.02 / 0.53
GREAT
|
| Average 1M Daily Value |
86.41 M
|
| Average 1W Daily Value |
65.54 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
66% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:23:56 |
| Symbol | TGTX |
| Name | TG THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 153.08 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,608.98 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
Phone: 212 554 4484
Website: https://www.tgtherapeutics.com
Employees: 399
Sector: Healthcare >> Biotechnology
Description: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
